Renin–angiotensin-aldosterone system (RAAS) inhibitors are thought to be capable of reducing the left ventricular afterload in AS patients, thereby alleviating myocardial hypertrophy and fibrosis [32]. This evidence concerns the gene REN and aortic stenosis.